


14

GP-1614 #3
RECEIVED 11-13-00
Jm

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: COHN and CARSON

Application No.: 09/658,261 ✓



NOV 02 2000

TECH CENTER 1600/2000

Filed: September 8, 2000

For: **Methods of Treating and Preventing Congestive Heart Failure With
Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate**

Attorney Docket No.: 102258.288

Assistant Commissioner of Patents
Washington, DC 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 form.


The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art.

A copy of each of the documents listed on the attached PTO-1449 form is submitted herewith.

This Information Disclosure Statement is being filed within three months of the filing date of the application. Accordingly, no fee is due.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 form with the next communication from the Patent Office.

Respectfully submitted,


Edward D. Grieff
Registration No. 38,898

Date: October 27, 2000
HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400